Related Experiment Video

Updated: Jun 29, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

360

Research and Development Progression of Oridonin for Hematological Malignancies Therapy

Hui Feng1, Runyu Yang1, Yue Du1

  • 1Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, No.277 Yanta West Road, Xi'an, Shaanxi, 710061, China.

Current Medicinal Chemistry
|March 29, 2024
PubMed

Insights

Oridonin, a compound from Isodon herbs, shows significant anti-tumor effects, particularly in hematological malignancies. Further research into its multi-target mechanisms is warranted.

Area of Science:

  • Pharmacology
  • Natural Products
  • Oncology

Background:

  • Oridonin is a tetracyclic diterpenoid from Isodon species.
  • Extensive research since 1976 highlights its in vivo anti-tumor activity.
  • Recent studies confirm oridonin's efficacy across various cancers, especially hematological malignancies.

Purpose of the Study:

  • To systematically review the anti-tumor effects of oridonin in hematological malignancies.
  • To elucidate the specific anti-cancer mechanisms of oridonin.
  • To explore the therapeutic potential of oridonin and its derivatives.

Main Methods:

  • Systematic literature review of studies on oridonin's anti-tumor effects.
  • Analysis of oridonin's mechanisms including protein regulation, apoptosis pathways, ROS generation, and miRNA modulation.
  • Examination of combination therapy and derivative development.

Main Results:

  • Oridonin demonstrates significant anti-tumor activity in hematological malignancies.
  • Mechanisms include regulating cancer proteins, activating apoptosis, increasing reactive oxygen species (ROS), and modulating chaperone proteins and miRNA.
  • Oridonin derivatives and combination therapies show promise.

Conclusions:

  • Oridonin exhibits broad-spectrum anti-tumor activities.
  • It functions as a multi-target agent against hematological malignancies.
  • Oridonin warrants further investigation for cancer therapy development.
Keywords:
Oridoninantitumor activitychemotherapy.hematological malignanciesimmunotherapymolecular mechanisms

More Related Videos

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.4K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.7K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K